[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:t-cell-histiocyte-rich-large-b-cell-lymphoma:bcl6-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"T-Cell\u002FHistiocyte-Rich Large B-Cell Lymphoma","BCL6 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06649812","Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and\u002For Refractory Aggressive B-cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:17.877565Z","2026-06-16T05:54:07.922088Z",{"nct_id":17,"title":18,"phases":19,"status":20,"updated_at":21,"content_modified":22},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":24,"title":25,"phases":26,"status":28,"updated_at":29,"content_modified":30},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[27],"Phase 1","ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z"]